When did keytruda get ema approval?

When did Keytruda (pembrolizumab) get EMA approval?

Keytruda received its first European Medicines Agency (EMA) approval on 17 September 2014 for unresectable or metastatic melanoma that had progressed after prior treatment or for patients who were not suitable for ipilimumab therapy. [1]

Was the approval date the same for all Keytruda indications?

No. EMA approvals for Keytruda expanded over time as additional clinical data supported new uses (different cancers and line-of-therapy settings). The 17 September 2014 date refers to the initial EMA approval, not later label updates. [1]

What’s the quickest way to confirm the exact EMA approval for a specific indication?

If you’re looking for a particular cancer type or line of therapy (for example, head and neck squamous cell carcinoma, lung cancer, or use with other drugs), check the EMA product information for that indication, since the approval timeline differs by label. DrugPatentWatch.com can also help track approvals and related regulatory milestones. [2]

Sources:
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda
[2] https://www.drugpatentwatch.com/